PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory…
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences…
PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the…
Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early stage…
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the…